Business Wire

NY-TERRAFORMATION

3.11.2022 08:22:41 CET | Business Wire | Press release

Share
Terraformation Launches World’s First Biodiversity-focused, Carbon-funded Forest Accelerator to Create More Global Land Restoration Projects

Terraformation, a global reforestation company, has launched the Seed to Carbon Forest Accelerator, the world’s first biodiversity-focused, carbon-funded forest accelerator program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005421/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Photo: The Kilimanjaro Project (Photo: Business Wire)

In the next decade, the world will need thousands of new reforestation teams to capture carbon at scale and limit the impacts of climate change. The new forest accelerator will help meet this need by providing forestry teams with the tools to launch restoration projects and succeed at scale. These include early-stage financing, training in resilient native ecosystem restoration, and tools to increase project transparency in critical early stages.

This wraparound platform to launch emerging forestry teams is unique in the industry and brings much-needed support to expand the supply of forest carbon.

The carbon buyers and companies who provide early financing to accelerator cohorts lock in access to the premium-quality carbon credits the projects generate. By providing this financing, buyers secure access to a portfolio of verified carbon credits from geographically diverse projects selected by the company’s carbon science team. Terraformation is looking to connect with finance partners to launch a new accelerator cohort early next year.

The accelerator program is a direct response to the largest bottlenecks to mass-scale restoration: in a recent Terraformation survey of 230 forestry organizations around the globe, 95% of respondents said funding was their biggest concern.[1]

The accelerator builds on Terraformation’s successful pilot restoration projects. Since the company began its global programs in 2020, it has successfully launched 16 restoration projects across 11 countries and created more than 400 new sustainable jobs.

Yishan Wong, founder and CEO of Terraformation, said: “The planet needs to rapidly scale reforestation efforts to address the climate crisis. And more investors than ever are looking for opportunities in carbon capture. But there hasn’t been a clear vehicle providing those investors access to high-quality carbon credits. At the same time, communities around the world are launching vital restoration efforts, but lack the funding, training and technology they need to scale.

“Our accelerator will rapidly expand the number of high-quality forest restoration projects and increase the planet’s capacity for carbon capture.”

María José Iturralde, co-founder of Humans for Abundance, a Terraformation restoration partner, said: “Funding can turn land management around by supporting new sustainable business models that replace deforestation for profit. Startup capital creates opportunities for training, education and infrastructure that allows communities to sustainably restore ecosystems and commercialize their new products in a new way.”

Apply to the accelerator
Applying to and participating in the Seed to Carbon Forest Accelerator is free and open to all forestry teams that prioritize biodiversity and benefits to local communities. Interested organizations and forestry teams are invited to apply to the accelerator beforeNovember 27, 2022. Read more and apply here.

Selected teams will receive a feasibility study to assess carbon project viability on their land, as well as access to expert training in seed collection and banking, biodiverse forest restoration, sustainable business models, marketing and finance. Teams will also receive access to carbon buyers, as well as to new, state-of-the-art project tracking software to streamline monitoring, reporting and verification of project progress, and more. Terraformation will encourage forestry teams to promote women’s leadership, offer community education and create sustainable, local economic impact.

Forestry teams selected to participate in the first cohort will be announced in early 2023.

Fund new forest carbon projects
Carbon buyers and companies interested in funding accelerator forest projects and accessing premium-quality, biodiverse, verified carbon credits can learn more here.

*ENDS*

NOTE TO EDITORS:

About Terraformation

Terraformation is dedicated to restoring the world’s forests to stabilize our climate, revive ecosystems, and build thriving communities.

The company hosts a forest carbon accelerator, supporting early-stage forestry teams to launch, build, and scale biodiverse reforestation projects. In addition to producing high-quality, verified carbon credits, these projects generate complementary sustainable revenue streams to support local economies.

Terraformation’s current partner network spans five continents and includes diverse landowners and organizations. It was founded in 2019 by Yishan Wong, former CEO of Reddit.

Footnotes

[1] Terraformation research conducted in summer 2022 with a survey of 230 respondents from 63 countries. Interviews were also completed with 70 respondents from 29 countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005421/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye